Recurrence clinical trials

The registry lists 3,523 studies for Recurrence across more than 10 countries. 870 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Recurrence studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 1,434
Recruiting: 634
Status unknown: 425
Terminated: 422
Not yet recruiting: 209
Active, not recruiting: 203

Phase

Phase 2: 1,351
Phase 1: 1,107
Phase 3: 309
Phase 4: 124
Early Phase 1: 70

Where

United States: 1,445
China: 683
France: 382
Spain: 301
Canada: 294
Italy: 289

Who runs them

M.D. Anderson Cancer Center (62) · Celgene (53) · Novartis Pharmaceuticals (50) · Memorial Sloan Kettering Cancer Center (48) · National Cancer Institute (NCI) (39) · Sun Yat-sen University (36) · Fred Hutchinson Cancer Center (31) · AbbVie (27)

Coming up

94phase 3 studies under way

300studies finish main data collection within a year15 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Nov 2026A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer · Phase 3 · Tesaro, Inc.
Dec 2026A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma · Phase 3 · Karyopharm Therapeutics Inc
Dec 2026A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS]) · Phase 3 · TJ Biopharma Co., Ltd.
Dec 2026A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy · Phase 3 · M.D. Anderson Cancer Center
Jan 2027A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) · Phase 3 · Celgene
Feb 2027A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). · Phase 3 · Pfizer
Mar 2027Study of Out of Specification for Tisagenlecleucel · Phase 3 · Novartis Pharmaceuticals
Apr 2027Study to Evaluate Efficacy and Safety of Gyntima® Balance in Preventing Recurrences of Bacterial Vaginosis · Phase 3 · Kaneka Americas Holding Inc.
May 2027Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer · Phase 3 · St. Olavs Hospital
May 2027COLLISION RELAPSE Trial · Phase 3 · Amsterdam UMC, location VUmc

Who these studies take

Of the 634 Recurrence studies recruiting now, 345 (54%) set no upper age limit and 232 (37%) stop at 75 or younger. 117 (18%) take children under 18. 39 (6%) are for women only and 7 (1%) for men only; 26 (4%) take healthy volunteers.

Recruiting studies that take each age, of 634
Age	Women	Men
10	81 (13%)	80 (13%)
18	583 (92%)	554 (87%)
30	581 (92%)	549 (87%)
40	575 (91%)	542 (85%)
50	561 (88%)	533 (84%)
65	553 (87%)	526 (83%)
75	481 (76%)	458 (72%)
85	366 (58%)	350 (55%)

Across all 3,523 studies, recruiting or not: 33% stop at 75 or younger and 19% at 65; 21% take children; 7% are for women only and 1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Recurrence studies take

Of 392 phase 2 interventional studies under Recurrence, half reached primary completion within 49 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	49 mo34–76 · 377 studies	45 mo32–65 · 199 studies	55 mo35–90 · 178 studies
Phase 1/2	76 mo44–129 · 196 studies	81 mo44–121 · 104 studies	69 mo49–129 · 92 studies
Phase 2	49 mo30–76 · 392 studies	35 mo25–57 · 124 studies	53 mo37–96 · 268 studies
Phase 3	55 mo33–86 · 120 studies	45 mo33–74 · 81 studies	—
Phase 4	41 mo24–67 · 46 studies	—	—
Interventional, no phase	43 mo23–76 · 292 studies	—	43 mo23–76 · 278 studies
Observational	53 mo32–119 · 184 studies	38 mo27–59 · 30 studies	56 mo33–155 · 154 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out